CoChat

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine ( Lantus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)

Open access
Rosenstock, J., Hollander, P., Bhargava, A., Ilag, L. L., Pollom, R. K., Zielonka, J. S., Huster, W. J., Prince, M. J. · 2015 · Diabetes, Obesity and Metabolism
Cited by 111

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aims: To compare the efficacy and safety of LY2963016 insulin glargine ( LY IGlar ) and the reference product ( L antus®) insulin glargine ( IGlar ) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes ( T2D ). Methods: This phase III , randomized, double‐blind, 24‐week study enrolled patients with T2D who were insulin‐naïve [glycated haemoglobin ( HbA1c ) ≥7 and ≤11.0%] or previously on IGlar ( HbA1c ≤11%) and treated with ≥2 oral antihyperglycaemic medications. Patients were randomized to receive once‐daily LY IGlar (n = 376) or IGlar (n = 380) for 24 weeks. The primary efficacy outcome was to test the non‐inferiority (0.4% and then 0.3% margin) of LY IGlar to IGlar , as measured by change in HbA1c from baseline to 24 weeks. Results: Both treatment groups had similar and significant (p < 0.001) within‐group decreases in mean HbA1c values from baseline. LY IGlar met non‐inferiority criteria compared with IGlar for change in HbA1c from baseline [−1.29 vs −1.34%; respectively, least‐squares mean difference 0.052% (95% confidence interval −0.070 to 0.175); p > 0.05]. There were no treatment differences (p > 0.05) in fasting plasma glucose, proportion of patients reaching HbA1c <7% or insulin dose at 24 weeks. Adverse events, allergic reactions, weight change, hypoglycaemia and insulin antibodies were similar between treatment groups. Similar findings were observed in patients who were insulin‐naïve or previously treated with IGlar at baseline. Conclusions: Both LY IGlar and IGlar , when used in combination with oral antihyperglycaemic medications, provided effective and similar glucose control with similar safety profiles in patients with T2D .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12482

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 111

Metadata

Authors
Rosenstock, J., Hollander, P., Bhargava, A., Ilag, L. L., Pollom, R. K., Zielonka, J. S., Huster, W. J., & Prince, M. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-05-31
Volume
17
Issue
8
Pages
734-741
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2140451842
Cited by
111
References
5
FWCI
14.18
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.